concall.in

Gland Pharma Limited Q2 FY27 concall - US revenue up 42%, new capacity expansion 📊 Financial Performance • Revenue up 23% YoY to ₹1,834cr. • Adjusted EBITDA at ₹503cr. Margin at 27%. • PAT up 58% YoY to ₹291cr. • Net cash of about ₹3,222cr. 🧪 Business Segments • CDMO revenue up 31% YoY to ₹823cr, 45% of total revenue. • Critical injectables revenue up 18% YoY to ₹1,011cr. • CDMO margins about 5–10% better than own products. • Cenexi revenue at €41 million with a €6 million EBITDA loss on planned shutdowns. 🌍 Markets & Quality • US revenue up 42% YoY to ₹1,180cr. 4 US launches in the quarter. • Europe and regulated markets up 23% YoY to ₹411cr. • Rest of World hit by delayed Saudi NUPCO tender results. • Vizag oncology plant cleared US FDA inspection with zero observations. 🚀 Capex & Pipeline • New ₹1,000cr brownfield expansion with 3 vial lines, operational from FY30. • Total capex plan now ₹3,000cr, adding 300–400 million units of capacity. • Liquid vial utilisation at 92%. Greenfield project started in Vizag. • Term sheet signed to in-license a second long-acting injectable from China, a USD 2 billion product. 🎯 Management Guidance & Outlook - Maintained • FY27 revenue growth guidance kept at 15% in constant currency. • Cenexi expected to return to profitability from Q3. • GLP-1 CDMO launches expected in Q1 or Q2 of next year. • Saudi tender results expected this quarter. Rest of World seen improving. 🔗 Link to full concall in thread for reference. Disc: This is not a buy or sell recommendation. Shared for educational and informational purposes only. #GLAND #Q2FY27 #Concall

Jubilant FoodWorks Limited Q2 FY27 concall - Steady growth, commodity cost pressure 📊 Financial Performance • Revenue up 11.8% YoY to ₹2,608cr. • EBITDA up 7.3% YoY to ₹513cr. Margin at 19.7% vs 20.5%. • Net profit down 42.6% YoY to ₹112cr. • Monthly active users up 25%. Monthly transacting users up 9%. 🍕 Domino's & Demand • Price hikes of 140–200 bps taken, calibrated by channel and daypart. • New launches now drive almost a double-digit share of topline growth. • Over 100 of about 400 stores refurbished. Rest due in about 3 quarters. • D2C channel grew at overall revenue level for the first time. 💲 Costs & Margins • Inflation seen in cheese, chicken and vegetables. • Cheese supply covered for the current financial year. • About 200 bps hit from unplanned costs like LPG and wage inflation. • Drag from emerging brands on margins falling faster than planned. 🍗 Popeyes & International • Popeyes positioned as the second growth engine. • Target daily sales per Popeyes store close to ₹1 lakh. • Popeyes gross margin has up to 200 bps more upside. • Turkey's negative LFL is due to hyperinflation accounting. Transactions are growing. 🎯 Management Guidance & Outlook - Maintained • FY27 LFL growth guidance kept at 5–7%. Q3 planned within that range. • 200 bps margin expansion goal retained. • Popeyes openings guided at 40–45 stores a year. • Further price hikes possible if commodity inflation continues. 🔗 Link to full concall in thread for reference. Disc: This is not a buy or sell recommendation. Shared for educational and informational purposes only. #JUBLFOOD #Q2FY27 #Concall

Voltas Q2 FY27 results - RAC volumes up 32%, profit rises on low base Total income: ₹2,746 crore (+13.8% YoY) PAT: ₹48 crore (+50% YoY) • Room AC volumes grew 32%, market share at 17.4% • Unitary Cooling revenue rose 29%, profitability improved despite input costs • Voltbek posted record Q2 sales, gaining share in appliances • Projects order book stands above ₹6,800 crore • Engineering Products segment grew 30%+, led by mining equipment Disc: Not a buy / sell recommendation. #VOLTAS #Q2FY27 #Results

Gland Pharma Q2 FY27 results - Strong growth, CDMO up 31%, US surge Revenue: ₹1,833.6 crore (+23% YoY, +2% QoQ) EBITDA: ₹480.4 crore (+53% YoY, -3% QoQ) PAT: ₹290.8 crore (+58% YoY, -8% QoQ) • CDMO business grew 31% YoY, now 45% of revenue • Critical injectables grew 18% YoY, contributing 55% of revenue • US sales jumped 42% YoY, India and RoW declined • Adj. EBITDA margin expanded to 27% from 23% • USFDA: zero observations at VSEZ, four procedural at Dundigal Disc: Not a buy / sell recommendation. #GLAND #Q2FY27 #Results

Sigma Advanced Systems Q2 FY27 results - Record quarter, big export wins, board changes Revenue: ₹417.07 crore (+11.43% QoQ) EBITDA: ₹82.28 crore (+35.06% QoQ) PAT: ₹52 crore vs ₹38 crore in Q1 FY27 • New £125 mn Rolls-Royce LTA adds to ₹3,800 crore deal • ₹1,013 crore North American order for 155mm artillery shells • Further ₹973 crore Base Bleed and ₹174 crore subsystem orders • Bromford UK acquired, Sri City aerospace plant began production • Two independent directors and one non-executive director resigned today Outlook: Management targets 2-4% EBITDA improvement by end FY27. Disc: Not a buy / sell recommendation. #SIGMAADV #Q2FY27 #Results

Nuvama Wealth Q2 FY27 results - Operating PAT up 26%, record wealth flows Revenue: ₹937 crore (+21% YoY) Operating PAT: ₹319 crore (+26% YoY) Reported PAT: ₹303.48 crore (+19.5% YoY) • Wealth Management PBT rose 22% to ₹184 crore • Record quarterly MPIS net new money of ₹3,289 crore • Asset Services revenue jumped 53% YoY to ₹245 crore • Capital Markets revenue grew 9% despite softer markets • Client assets reached ₹5.5 trillion, up 25% YoY, RoE ~29% Outlook: Management says Nuvama remains "in the early innings of a much larger opportunity". Disc: Not a buy / sell recommendation. #NUVAMA #Q2FY27 #Results

AvenuesAI Q2 FY27 results - Revenue up 47%, thin EBITDA growth, take rate dips Revenue: ₹2,879.24 crore (+47% YoY) EBITDA: ₹98.88 crore (+3% YoY) PAT: ₹71.70 crore (+6% YoY) • Net revenue declined 1% YoY to ₹151.32 crore • Payments TPV rose 19% QoQ to about ₹1.77 lakh crore • Net take rate moderated 4% to 5.06 bps on competitive pricing • Priorities: unlock Rediff, expand CCAvenue in US, build TISco AI Outlook: Management retains previously communicated FY27 revenue guidance of ₹11,000–13,000 crore, and is monitoring possible UPI MDR changes. Disc: Not a buy / sell recommendation. #CCAVENUE #Q2FY27 #Results

Cholamandalam Financial Holdings Q2 FY27 results - PAT up 25%, insurance arm slips to loss Total income: ₹11,388 crore (+19% YoY) PAT: ₹1,520 crore (+25% YoY) • Chola Investment disbursements jumped 47% to ₹35,872 crore • Chola Investment PAT rose 41% to ₹1,630 crore • Lending AUM grew 23% to ₹2,68,009 crore • Chola MS General Insurance posted ₹120 crore quarterly loss • Insurance hit by NATCAT events and elevated motor OD claims Disc: Not a buy / sell recommendation. #CHOLAHLDNG #Q2FY27 #Results